
Quarterly ResultAug 4, 2026, 04:39 PM
Adaptive Biotechnologies Q2 Revenue Up 21.5%; Net Loss Widens
AI Summary
Adaptive Biotechnologies reported a 21.5% increase in revenue for the second quarter of 2026, reaching $71.55 million. However, the company's net loss widened to $39.94 million, partly due to a $23.73 million loss on revenue interest liability extinguishment. The company also issued $334.88 million in convertible senior notes and repurchased $25.00 million of common stock during the first half of 2026, significantly boosting its cash position.
Key Highlights
- Revenue for Q2 2026 increased 21.5% to $71.55 million from $58.88 million in Q2 2025.
- Net loss for Q2 2026 widened to $39.94 million, compared to $25.59 million in Q2 2025.
- Net loss per share for Q2 2026 was $(0.25), up from $(0.17) in Q2 2025.
- Issued $334.88 million in convertible senior notes during the six months ended June 30, 2026.
- Extinguished revenue interest liability, resulting in a $23.73 million loss.
- Cash and cash equivalents increased to $169.87 million as of June 30, 2026, from $70.50 million.
- Repurchased $25.00 million of common stock during the six months ended June 30, 2026.
Price Impact
More from ADPT